

Remarks

Claims 49, 50, 52, 53, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76 and 77 are pending. Claims 51, 54 and 55 have been newly cancelled. Claims 49, 50, 52, 53, 56, 57 and 58 have been newly amended. Claims 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76 and 77 are newly added. Support for these amendments are found throughout the specification and in the claims as originally filed. No new matter has been entered. All newly added claims are encompassed by Group I of the restriction requirement drawn to methods of identifying biomarkers and methods for diagnosis and prognosis of bladder cancer, further restricted to the ADAM9 gene.

Claims 50, 68, 69 and 70 clarify that said levels of RNA encoded by said gene are in blood samples which include all of the types of leukocytes in whole blood, i.e. of blood samples which include granulocytes in addition to mononuclear cells (T-lymphocytes, B-lymphocytes and monocytes). This phrase finds clear support in the specification, including at Figure 5C which shows standardized levels of insulin gene expression in each of the fractions of leukocytes which collectively constitute unfractionated leukocytes, i.e. granulocytes, T-lymphocytes, B-lymphocytes and monocytes (labeled “G.R.”, “CD 3+”, “CD19” and “MONO”, i.e., respectively). It is well known to the ordinarily skilled artisan that CD3 and CD19 are specific cell surface markers of T-lymphocytes and B-lymphocytes (refer, for example, to the enclosed Abstract of Casey *et al.*, 1988. simplified plastic embedding and immunohistologic technique for immunophenotypic analysis of human hematopoietic and lymphoid tissues. Am J Pathol. 131:183-9). The fact that granulocytes (G.R.), lymphocytes [T-lymphocytes (CD 3+) and B-lymphocytes (CD19+)] and monocytes (MONO) represent all of the types of leukocytes found in blood is taught at Fig. A.23 Immunobiology. Garland Publishing. 2001. Fifth Edition. Janeway, Travers, Walport, and Shlomchik, eds. (attached) which clearly teaches that leukocytes are composed of granulocytes and mononuclear cells, and that the latter are composed of lymphocytes and monocytes. Additional support for the term “leukocytes” is found at paragraphs [0004] and [0088] of the published application (US20040248169).

New independent claim 71 claims a method of classifying gene expression in a test subject relative to a population of control subjects that includes subjects having bladder cancer

and healthy subjects. New claim 71 comprises a step of quantifying a level of RNA encoded by an ADAM9 gene in a blood sample from the test subject, and a subsequent step of comparing the level in the sample from the test subject with levels of RNA encoded by the gene in blood samples from the subjects having bladder cancer and in blood samples from the healthy subjects. The new claim concludes that a statistically significant determination that the level in the sample from the test subject is similar to the levels in the samples from the subjects having bladder cancer and is different from the levels in the samples from the healthy subjects classifies the level in the sample from the test subject with the levels from the samples from the subjects having bladder cancer; and that a statistically significant determination that the level in the sample from the test subject is different from the levels in the samples from the subjects having bladder cancer and is similar to the levels in the samples from the healthy subjects classifies the level in the sample from the test subject with the levels in the samples from the healthy subjects. Support for reciting comparison of biomarker RNA levels of a test subject with those of control subjects having a disease (i.e. bladder cancer) and with those of healthy control subjects, and determination of a statistically significant difference or similarity therebetween can be found in the published application, for example at paragraph [0127] (“*When comparing two or more samples for differences, results are reported as statistically significant when there is only a small probability that similar results would have been observed if the tested hypothesis (i.e., the genes are not expressed at different levels) were true.*”), and at paragraph [0128] (“*When comparing two or more samples for similarities, results are reported as statistically significant when there is only a small probability that similar results would have been observed if the tested hypothesis (i.e., the genes are not expressed at different levels) were true.*”), respectively. Support for reciting classification of a test subject level relative to specific control levels can be found, for example, at claim 12 as originally filed (“*d) determining whether the level of said one or more gene transcripts of step a) classify with the levels of said transcripts in step b) as compared with the levels of said transcripts in step c)*”), at paragraph [0135] (relating to “*Methods that can be used for class prediction analysis*”), [0351] (“*Blood samples were taken from patients who were diagnosed with bladder cancer as defined herein. Gene expression profiles were then analyzed and compared to profiles from patients unaffected by any disease.*”), and [0360] (“*Blood samples were taken from patients who were diagnosed with early or advanced late stage bladder cancer*

as defined herein. Gene expression profiles were then analysed and compared to profiles from patients unaffected by any disease.”).

Claims Rejection - 35 U.S.C. 112 2nd

Claims 51, 52, 53, 54, 55, 56, 57 and 58 are rejected under 35 U.S.C. 112, 2nd paragraph as being indefinite for failing to particularly point out and distinctly claim the subject matter which Applicant regards as the invention.

The office action indicates that the recitation of “unfractionated samples of lysed blood” is unclear. Although Applicant respectfully traverses, Applicant has canceled independent claim 51 and dependent claims 54 and 55 solely for the purposes of advancing prosecution without prejudice for pursuing the unclaimed subject matter in another application, rendering the rejection of claims 51, 54 and 55 moot. Applicant has amended dependent claims 52, 53, 56 and 57 to be dependent from claim 49 or newly added claim 61, which do not recite the phrase “unfractionated samples of lysed blood”.

Claims Rejection - 35 U.S.C. 112 1st

Claims 51, 52, 53, 54, 55, 56, 57 and 58 are rejected under 35 U.S.C. 112, 1st paragraph, as failing to comply with the written description requirement on the grounds that the phrase “unfractionated samples of lysed blood” is new matter. Although Applicant respectfully traverses, Applicant has canceled claim 51 and dependent claims 54 and 55 solely for the purposes of advancing prosecution without prejudice for pursuing the unclaimed subject matter in another application, rendering the rejection of claims 51, 54 and 55 moot. Applicant has amended dependent claims 52, 53, 56 and 57 to be dependent from claim 49 or newly added claim 61, which do not recite the phrase “unfractionated samples of lysed blood”.

Claims 49, 50, 51, 52, 53, 54, 55, 56, 57 and 58 are rejected under 35 U.S.C. 112, 1st paragraph, as failing to comply with the enablement requirement.

Applicant respectfully traverses. Applicant disagrees with the rejection’s assertion that the skilled artisan would have required an undue amount of experimentation to make and/or use

the claimed invention in view of the breadth of the claims, the amount of guidance provided by the specification, and the level of predictability in the art.

The rejected claims include the steps of determining the level of RNA encoded by an ADAM9 gene in a blood sample obtained from a human test subject and comparing it to the level of control RNA encoded by the gene in blood samples of control subjects, where the comparison is indicative of bladder cancer in said human test subject.

Applicant specifically traverses the statement on page 4 of the office action that “*the independent claim, as written, states that a comparison of a human test subject ADAM9 RNA level in a blood sample to a control indicates that bladder cancer is present in the test subject*”, and the statement on page 5 of the office action ‘*The claims are extremely broad because they... set forth that any or all comparison between a test subject and RNA level from “control subjects” is indicative of disease*’. Applicant clarifies that the phrase “wherein said comparison of said quantified level of step (a) with said quantified level of said control subjects is indicative of bladder cancer in said human test subject” of independent claim 49, is a narrowing limitation, limiting the claim to only those comparisons which are indicative of the test subject having bladder cancer, and excluding those comparisons which do not indicate that the test individual has bladder cancer.

However, in the interest of expediting prosecution, Applicant has added new claims which more clearly set forth the subject matter of the newly cancelled claims. Specific points raised in the instant enablement rejection will be addressed to the extent that they are relevant to the newly added claims.

The rejection asserts that the claims are broad with respect to “control subjects”, indicating that “control subjects” could encompass patients with bladder cancer, healthy patients, patients with some other disease such as lymphoma or a particular stage of bladder cancer (page 5 of the office action). The instant claims recite two clearly defined sets of controls; subjects having bladder cancer and healthy controls. At least one claim, claim 64, limits the controls to healthy subjects.

The office action states that the claims do not “set forth the direction of the difference necessary to indicate bladder cancer” (p. 5 of the Office Action) and suggests that without

providing this information, the mere observation of differences is an unpredictable indicator of bladder cancer.

The Applicant respectfully submits that the invention is taught in such terms that one skilled in the art can make and use the claimed invention, including the use of the elected biomarker ADAM9 as an indicator of rheumatoid arthritis as described in the claims without disclosing the direction or the level of difference that exists between patients having rheumatoid arthritis and individuals not having rheumatoid arthritis. The Applicant has identified the elected gene ADAM9 as differentially expressed as between individuals diagnosed as having rheumatoid arthritis and individuals not having rheumatoid arthritis by demonstrating a statistical difference in the level of RNA. The statistical significance of the differential expression of ADAM9 is evidenced by its P value of 0.000126, as listed in Example 19 (Table 3J). Therefore the Applicant has taught that there is a significant difference in differential expression for ADAM9 as between a population of individuals having bladder cancer and a population of individuals not having bladder cancer, and further has taught to compare the level of expression of ADAM9 in a test individual with populations having bladder cancer and populations not having bladder cancer using classification methods to determine the similarity or difference in gene expression levels as between the test subject and the tested populations (see paragraphs [0127] to [0128] and [0131] to [0137] in addition to [0351] to [0360]). Independent claims 49 and 71 require that the level of expression of RNA corresponding to ADAM9 be compared with the level of ADAM9 in other individuals who have bladder cancer and require at a minimum a statistically significant similarity as between the test subject and control subjects having bladder cancer before the level of gene expression of ADAM9 is considered to be indicative of bladder cancer or a candidate for bladder cancer, respectively.

Furthermore, the Applicant contends that it does not require undue experimentation for one of skill to determine the inherent direction or level of the statistically significant differential expression required for the claimed methods of detecting a bladder cancer, given the widely established and validated analytical tools for analyzing gene expression levels. Therefore, it is not necessary for the Applicant to have taught the exact direction or level of difference between the two populations for one of skill to practice the invention. The Applicant has provided sufficient information by teaching that there ADAM9 is differentially expressed and that the

differential expression between healthy and control subjects is significant as between the populations.

The Office Action also suggests that field of analyzing expression profiles “remains highly unpredictable years after the filing of the instant application...” (p. 9 of the Office Action) citing Osman et al.. The Applicant submits that the differential expression of ADAM9 as between subjects having bladder cancer and subjects not having bladder cancer is, in fact, predictable. In Osman et al., blood cell gene expression profiles of bladder cancer patients (i.e. 16 individuals having bladder cancer) were compared with 10 healthy individuals. A selection of the genes identified as demonstrating statistically significant difference ($P<0.05$) (p.3376) were tested using RT-PCR on yet an additional sample set of 20 bladder cancer patients and 14 control patients (p. 3376, second column) and IGFBP7 continued to verify as a gene which was differentially expressed as between the two populations (see page 3377, second column). As stated in the Manual of Patent Examining Procedure at 2164.03: the “predictability or lack thereof” in the art refers to the ability of one skilled in the art to extrapolate the disclosed or known results to the claimed invention. In the instant application, the disclosed result is a statistically significant differential expression in the level of ADAM9 RNA as between subjects having bladder cancer and subjects not having bladder cancer, the statistically significant difference having a p value equal to 0.000126, as indicated in Table 3J of the instant specification.

The rejection asserts that the specification does not establish any particular level of expression of ADAM9 which is sufficient to detect bladder cancer to the exclusion of other disorders, at page 8 of the office action.

The office action specifically contends that ADAM9 expression in blood may not be indicative of bladder cancer on the grounds that Stuhlmuller *et al.* teaches that ADAM9 is differently expressed in blood cells of patients having rheumatoid arthritis and healthy controls. Applicant wishes to point out, however, that at most Stuhlmuller *et al.* can be argued to teach that this gene is differently expressed in highly purified CD14+ monocytes (paragraph [0023]) which constitute as little as 2%, and at most 9%, of the RNA-expressing leukocytes of blood (refer, for example, to enclosed Complete Blood Count Table, Merck Manual). This is in sharp contrast to the instant claims which distinctly relate to levels of ADAM9 RNA in blood

preparations which comprise unfractionated leukocytes, which encompass a large majority of non-CD14+ monocytes. Applicant respectfully submits that it would not be reasonable to expect that the differences in expression of ADAM9 in rheumatoid arthritis patients reported by Stuhlmuller *et al.* in such a small subset of leukocytes would be observable in rheumatoid arthritis patients when analyzing the entire population of unfractionated leukocytes, which includes about at least 10-fold, up to 50-fold greater numbers of non-CD14+ monocyte cell types. In addition, the purification process employed by Stuhlmuller *et al.* to obtain CD14+ monocytes involves positive selection via magnetic or FACS separation, which involves reacting the cells with anti-CD14 antibodies which bind the CD14 receptor, (paragraph [0023]). The CD14 molecule is a well known cell surface receptor capable of triggering signal transduction culminating in changes in RNA levels and cell activation (refer, for example, to enclosed abstract of: Kielian TL and Blecha F, 1995. CD14 and other recognition molecules for lipopolysaccharide: a review. *Immunopharmacology*. 1995 Apr;29(3):187-205). Treatment of monocytes with anti-CD14 antibodies has previously been shown to trigger cellular responses (refer, for example, to enclosed abstract of: Axtelle T and Pribble J., 2001. IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis. *J Endotoxin Res.* 2001;7(4):310-4). Thus, the apparent differences in ADAM9 expression in purified CD14+ monocytes reported by Stuhlmuller *et al.* may simply represent differential responses to anti-CD14 antibody treatment between the experimental groups tested. As such, Applicant submits that Stuhlmuller *et al.* cannot be reasonably considered to teach that ADAM9 RNA is differently expressed between rheumatoid arthritis patients and healthy controls in blood samples which comprise unfractionated leukocytes, as instantly claimed.

Nevertheless, solely for the purpose of expediting prosecution, Applicant has included the limitation in claims 65 and 67 that the recited comparison between a test subject and controls indicates that the test subject is a “candidate” for having bladder cancer. Applicant has also added new claim 71 which is a method of classifying ADAM9 gene expression in a test subject with that in bladder cancer patients or healthy control subjects.

The rejection contends that the claims may not be enabled due to insufficient replication of experimental results, on the grounds that that Lee teaches that data obtained from microarrays must be replicated in order to screen out false positive results (page 7), on the grounds that post-

filing reference Osman *et al.* teaches that the results of experiments such as those disclosed in the specification relating to differential expression of ADAM9 in blood of bladder cancer patients may be intrinsic to the cohort studied (page 9), and on the grounds that Newton *et al.* teaches that “replication of data is critical to validation” (page 10).

Applicant respectfully disagrees that insufficient replication is provided by the specification. Applicant submits that the results of the specification are valid, as evidenced by the attached declaration filed under 1.132 which discloses post-filing validation experiments using quantitative RT-PCR (QRT-PCR), an alternate technology relative to microarray analysis employed in the experiments disclosed at Example 19 of the specification, as well as using an independent cohort of control and disease subjects relative to those employed in the experiments disclosed at Example 19 of the specification, as well as those employed in Osman *et al.*, of record. The experiments disclosed in the declaration clearly show that RNA encoded by the gene ADAM9 is present at statistically different levels in blood of subjects having bladder cancer relative to healthy control subjects.

Furthermore, with regard to the passages of Osman *et al.* cited by the rejection to support the contention that there is a high level of unpredictability in the field, Applicant wishes to point out that this reference clearly concludes, despite any conservative academic reservations expressed therein, that biomarkers identified as described in this reference—and hence as described in the specification according to the rejection—can be used to differentiate bladder cancer patients from those having other genitourinary cancers or healthy controls. Namely, this reference clearly teaches that on balance biomarkers identified as described therein are “novel blood biomarkers of human urinary bladder cancer” (title) and can “distinguish bladder cancer from other types of genitourinary cancer and healthy controls” (abstract).

The office action states on page 7 that Wu et al (2001) teaches that gene expression data, such as microarray data, must be interpreted in the context of other biological knowledge, and that the conclusions that can be drawn from a given set of data depend on the particular choice of data analysis.

Applicant respectfully disagrees and submits that gene expression which is reproducible, and is correlated with the state of health or disease of the individual does not necessarily result directly from the state of disease of the individual. Rather these changes in expression may

simply represent a downstream side-effect of pathogenic processes, and it is not necessary that the biological relevance of the data be known to allow this difference in expression to be useful as a biomarker. For example prostate-specific phosphatase and prostate-specific antigen (PSA) were long used as biomarkers without an understanding of their function (refer, for example, to the enclosed abstracts of: Chu TM, 1990, Prostate cancer-associated markers. Immunol. Ser. 53:339-56; and Diamandis EP., 2000, Prostate-specific antigen: a cancer fighter and a valuable messenger? Clin Chem. 46:896-900).

The Examiner also argues, on the basis of post-filing art of Wu (2001) and Newton (2001), that many factors may influence the outcome of the data analysis and notes that conclusions depend on the methods of data analysis. While considerations such as variability, and normalization are of importance, these considerations are well understood by a person skilled in the art and have been applied for many years to permit development of biomarkers which are indicative of disease. These challenges are well understood, as are the routine experiments required to exemplify statistically significant differences in populations.

As grounds for lack of enablement due to a high level of unpredictability, the office action states on page 9 that Cheung et al. (2003) teaches that the natural variation in gene expression amongst different individuals is such that it is unpredictable as to whether or not any level of altered ADAM9 gene expression will be indicative of a presence or absence of bladder cancer.

Applicant respectfully disagrees that Cheung *et al.* constitutes grounds for non-enablement of the claims. Firstly, the results disclosed by Cheung *et al.* cannot be reliably extrapolated to primary blood samples since the lymphoblastoid cells employed by Cheung *et al.* are significantly modified relative to primary blood cells, due to being cultured cell lines generated by immortalization of primary human cells derived from "CEPH" families, as indicated in Reference no. 10 of Cheung *et al.* (Dausset *et al.*, 1990. Genomics 6:575; enclosed) at p. 575, right column, 1st paragraph. Applicant notes that immortalized cultured cell lines such as the lymphoblastoid cells taught by Cheung *et al.* undergo significant genetic modification such as strong genome-wide demethylation (refer, for example, to enclosed abstract of: Vilain *et al.*, 2000. DNA methylation and chromosome instability in lymphoblastoid cell lines. Cytogenet Cell Genet. 90:93), as a result of extensive *in-vitro* culturing in the absence of immune or

apoptotic mechanisms which function to eliminate mutated cells in the body. As such, immortalized CEPH lymphoblastoid cells may represent a particularly unsuitable cell type for modeling gene expression variability in primary blood cells. To the extent that Cheung et al. could still be considered to suggest that larger populations of diseased and control populations may be useful to determine what level of differential expression is indicative of disease amongst the population at large, Applicant submits that the extension of the experiments as outlined in the specification to additional individuals is merely routine. As is noted in *Re Wands* “*even a considerable amount of experimentation is permissible to practice the claimed methods, if it is merely routine, or if the specification in question provides a reasonable amount of guidance with respect to the direction in which the experimentation should proceed.*” (*Re Wands*, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988)).

Furthermore, the decision *In re Angstadt*, 190 U.S.P.Q. 218 (C.C.P.A. 1976) clearly states that even in an unpredictable art, and clearly permits the presence of a screening step to identify those embodiments which possess the desired activity is permissible. In fact, in *Angstadt*, the Court specifically dismissed the notion that the specification must provide a level of guidance that would predict the outcome of an experiment “with reasonable certainty before performing the reaction” and that “such a proposition is contrary to the basic policy of the Patent Act, which is to encourage disclosure of inventions and thereby to promote progress in the useful arts.” The “predictability or lack thereof” in the art refers to the ability of one skilled in the art to extrapolate the disclosed or known results to the claimed invention.

Applicant wishes to point out that in *In re Wands*, the court stated that “[e]nabling is not precluded by the necessity for some experimentation such as routine screening. However, experimentation needed to practice the invention must not be undue experimentation. ‘The key word is ‘undue’ not ‘experimentation’ (citing *In re Angstadt*, 537 F. 2d 498 at 504, 190 U.S.P.Q. 214 at 219 (C.C.P.A. 1976)). The Court also stated that “the test is not merely quantitative, since a considerable amount of experimentation is permissible, if it is merely routine, or if the specification in question provides a reasonable amount of guidance with respect to the direction in which the experimentation should proceed.” (citing *In re Jackson*, 217 U.S.P.Q. 804 at 807 (Bd. App. 1982)).

As such Applicant believes there is sufficient guidance provided by the specification and

that the art is sufficiently predictable such that the amount of experimentation to perform the subject matter within the instant claims is not undue.

In light of the amendments and above remarks, Applicant contends that the claims are fully enabled, and respectfully requests reconsideration and withdrawal of the instant rejections.

Conclusion

Applicant submits that all claims are allowable as written and respectfully request early favorable action by the Examiner. No new matter is added. If the Examiner believes that a telephone conversation with Applicant's attorney/agent would expedite prosecution of this application, the Examiner is cordially invited to call the undersigned attorney/agent of record.

Respectfully submitted,

Date: November 26, 2007

Amy DeClue 54849, Jr.
Name: Kathleen M. Williams
Registration No.: 34,380
Customer No.: 21874
Edwards Angell Palmer & Dodge LLP
P.O. Box 55874
Boston, MA 02205
Tel: 617-239-0100

Encl:

Abstract of: Axtelle T and Pribble J., 2001. IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis. *J Endotoxin Res.* 2001;7(4):310-4)

Abstract of Casey et al., 1988. simplified plastic embedding and immunohistologic technique for immunophenotypic analysis of human hematopoietic and lymphoid tissues. *Am J Pathol.* 131:183-9;

Abstract of: Chu TM, 1990, Prostate cancer-associated markers. *Immunol. Ser.* 53:339-56;

Abstract of: Diamandis EP., 2000, Prostate-specific antigen: a cancer fighter and a

valuable messenger? Clin Chem. 46:896-900);

Abstract of: Kielian TL and Blecha F, 1995. CD14 and other recognition molecules for lipopolysaccharide: a review. Immunopharmacology. 1995 Apr;29(3):187-205;

Abstract of: Vilain et al., 2000. DNA methylation and chromosome instability in lymphoblastoid cell lines. Cytogenet Cell Genet. 90:93;

Complete Blood Count Table, Merck Manual 2006;

Dausset et al., 1990. Genomics 6:575; and

Fig. A.23. Immunobiology. Garland Publishing. 2001. Fifth Edition. Janeway, Travers, Walport, and Shlomchik, eds.

1: J Endotoxin Res. 2003;9(6):385-9.

An overview of clinical studies in healthy subjects and patients with severe sepsis with IC14, a CD14-specific chimeric monoclonal antibody.

Axtelle T, Pribble J.

ICOS Corporation, 22021 20th Avenue SE, Bothell, WA 98021, USA.
taxtelle@icos.com

An overview and discussion of clinical studies with IC14, a chimeric monoclonal antibody directed against human CD14 is presented. These studies include phase 1 trials in: (i) healthy subjects; (ii) healthy subjects challenged with lipopolysaccharide (LPS); and (iii) patients with severe sepsis. The results from clinical studies of IC14 demonstrate this chimeric monoclonal antibody diminishes the systemic inflammatory response directed against LPS and may have potential as a treatment to prevent organ dysfunction in patients with severe sepsis. Furthermore, IC14 treatment was generally well-tolerated in both healthy subjects and severe sepsis patients and did not increase the incidence of secondary infections. Analysis of pharmacology data indicate that higher doses of IC14 are required to saturate membrane-bound CD14 receptors effectively in patients with severe sepsis than in healthy subjects. Finally, the results of non-clinical studies indicate that IC14 should only be administered with concurrent antimicrobial therapy in patients with infection.

PMID: 14733726 [PubMed - indexed for MEDLINE]

1: Am J Pathol. 1988 May;131(2):183-9.

A simplified plastic embedding and immunohistologic technique for immunophenotypic analysis of human hematopoietic and lymphoid tissues.

Casey TT, Cousar JB, Collins RD.

Department of Pathology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232.

Routine fixation and paraffin embedding destroys many hematopoietic and lymphoid differentiation antigens detected by flow cytometry or frozen section immunohistochemistry. On the other hand, morphologic evaluation is difficult in flow cytometric or frozen section studies. A simplified three-step plastic embedding system using acetone-fixed tissues embedded in glycol-methacrylate (GMA) resin has been found to provide both excellent morphologic and antigenic preservation. With our system, a wide variety of antigens are detected in plastic sections without trypsinization or prolonged embedding procedures; pan-B (CD19, CD22), pan-T (CD7, CD5, CD3, CD2), T-subset (CD4, CD8, CD1, CD25) markers as well as surface immunoglobulin and markers for myeloid and mononuclear-phagocyte cells are preserved. In summary, modifications of plastic embedding techniques used in this study simplify the procedure, apparently achieve excellent antigenic preservation, and facilitate evaluation of morphologic details in relation to immunocytochemical markers.

PMID: 3282442 [PubMed - indexed for MEDLINE]

1: Immunol Ser. 1990;53:339-56.

Prostate cancer-associated markers.

Chu TM.

Roswell Park Memorial Institute, New York State Department of Health, Buffalo.

Immunodiagnosis of prostate cancer is at a more advanced stage than that of most other tumors. Two well-known markers, prostatic acid phosphatase and prostate-specific antigen, have been used in the clinical management of patients. Prostate-specific antigen is a more sensitive and reliable marker than prostatic acid phosphatase. Serum prostate-specific antigen is effective in monitoring disease status, predicting recurrence, and detecting residual disease. Prostate-specific antigen is a tool for the histological differential diagnosis of metastatic carcinomas, especially in the identification of metastatic prostate tumor cells in distant organs and in the differentiation of primary prostate carcinoma from poorly differentiated transitional cell carcinoma of the bladder. Few data on biological function are available. Prostatic acid phosphatase functions as a phosphotyrosyl-protein phosphatase and prostate-specific antigen as a protease. Physiological function in the prostate remains to be elucidated. Several of the prostate-specific and prostate-tumor-associated antigens, as well as a putative prostate tumor-specific antigen, as recognized by monoclonal antibodies are available. Clinical evaluation of these potential markers is not yet available.

PMID: 1713065 [PubMed - indexed for MEDLINE]

1: Clin Chem. 2000 Jul;46(7):896-900.

Prostate-specific antigen: a cancer fighter and a valuable messenger?

Diamandis EP.

Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada. ediamandis@mtsinai.on.ca

BACKGROUND: Prostate-specific antigen (PSA) is a valuable prostatic cancer biomarker that is now widely used for population screening, diagnosis, and monitoring of patients with prostate cancer. Despite the voluminous literature on this biomarker, relatively few reports have addressed the issue of its physiological function and its connection to the pathogenesis and progression of prostate and other cancers.

APPROACH: I here review literature dealing with PSA physiology and pathobiology and discuss reports that either suggest that PSA is a beneficial molecule with tumor suppressor activity or that PSA has deleterious effects in prostate, breast, and possibly other cancers.

CONTENT: The present scientific literature on PSA physiology and pathobiology is confusing. A group of reports have suggested that PSA may act as a tumor suppressor, a negative regulator of cell growth, and an apoptotic molecule, whereas others suggest that PSA may, through its chymotrypsin-like activity, promote tumor progression and metastasis. **SUMMARY:** The physiological function of PSA is still not well understood. Because PSA is just one member of the human kallikrein gene family, it is possible that its biological functions are related to the activity of other related kallikreins. Only when the physiological functions of PSA and other kallikreins are elucidated will we be able to explain the currently apparently conflicting experimental data.

PMID: 10894830 [PubMed - indexed for MEDLINE]

!:: Immunopharmacology. 1995 Apr;29(3):187-205.

[Related Articles,](#)
[Links](#)



CD14 and other recognition molecules for lipopolysaccharide: a review.

Kielian TL, Blecha F.

Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, Manhattan 66506, USA.

Lipopolysaccharide (LPS) or endotoxin elicits a broad, non-specific cascade of events in vivo, resulting in secretion of a variety of potent mediators and cytokines produced primarily by activated macrophages and monocytes. The overproduction of these effector molecules, such as interleukin-1 and tumor necrosis factor-alpha, contributes to the pathophysiology of endotoxic shock. Cellular recognition of LPS involves several different molecules, including cluster of differentiation antigen CD14. A thorough understanding of the interaction of LPS with cells of the immune system is necessary before effective preventative or therapeutic measures can be designed to limit the host response to endotoxin. This review discusses the role of CD14 and other LPS-recognition molecules in LPS-mediated macrophage activation.

Publication Types:

- Review

PMID: 7542643 [PubMed - indexed for MEDLINE]

1: Cytogenet Cell Genet. 2000;90(1-2):93-101.

DNA methylation and chromosome instability in lymphoblastoid cell lines.

Vilain A, Bernardino J, Gerbault-Seureau M, Vogt N, Niveleau A, Lefrançois D, Malfoy B, Dutrillaux B.

Institut Curie-CNRS UMR 147, Cytogénétique Moléculaire et Oncologie, Paris, France.

In order to gain more insight into the relationships between DNA methylation and genome stability, chromosomal and molecular evolutions of four Epstein-Barr virus-transformed human lymphoblastoid cell lines were followed in culture for more than 2 yr. The four cell lines underwent early, strong overall demethylation of the genome. The classical satellite-rich, heterochromatic, juxtacentromeric regions of chromosomes 1, 9, and 16 and the distal part of the long arm of the Y chromosome displayed specific behavior with time in culture. In two cell lines, they underwent a strong demethylation, involving successively chromosomes Y, 9, 16, and 1, whereas in the two other cell lines, they remained heavily methylated. For classical satellite 2-rich heterochromatic regions of chromosomes 1 and 16, a direct relationship could be established between their demethylation, their undercondensation at metaphase, and their involvement in non-clonal rearrangements. Unstable sites distributed along the whole chromosomes were found only when the heterochromatic regions of chromosomes 1 and 16 were unstable. The classical satellite 3-rich heterochromatic region of chromosomes 9 and Y, despite their strong demethylation, remained condensed and stable. Genome demethylation and chromosome instability could not be related to variations in mRNA amounts of the DNA methyltransferases DNMT1, DNMT3A, and DNMT3B and DNA demethylase. These data suggest that the influence of DNA demethylation on chromosome stability is modulated by a sequence-specific chromatin structure. Copyright 2000 S. Karger AG, Basel.

PMID: 11060456 [PubMed - indexed for MEDLINE]

Diagnosis: Symptoms and Diagnosis of Blood Disorders: Merck Manual Home ...

| Complete Blood Count (CBC) | | |
|-------------------------------------|--|--|
| Test | What It Measures | Normal Values |
| Hemoglobin | Amount of this oxygen-carrying protein within red blood cells | Men: 14 to 17 grams per deciliter Women: 12.5 to 15 grams per deciliter |
| Hematocrit | Proportion of total blood volume made up of red blood cells | Men: 42 to 50% Women: 36 to 45% |
| Mean corpuscular volume | Average volume of individual red blood cells | 86 to 98 femtoliters |
| White blood cell count | Number of white blood cells in a specified volume of blood | 4,500 to 10,500 per microliter |
| Differential white blood cell count | <u>Percentages of the different types of white blood cells</u> | Segmented neutrophils: 34 to 75% Band neutrophils: 0 to 8% <u>Lymphocytes: 12 to 50%</u> Monocytes: 2 to 9% Eosinophils: 0 to 5% Basophils: 0 to 3% |
| Platelet count | Number of platelets in a specified volume of blood | 140,000 to 450,000 per microliter |
| Mean platelet volume | Average volume of platelets | 7 to 10 femtoliters |

Peripheral blood mononuclear cells can be isolated from whole blood by Ficoll-... Page 1 of 1



[Short Contents](#) | [Full Contents](#)

[Other books @ NCBI](#)

Navigation

About this book

Appendix I.
Immunologists'
Toolbox

Immunization.
The detection,
measurement,
and
characterization
of antibodies and
their use as
research and
diagnostic tools.

Isolation of lymphocytes.
Characterization of lymphocyte specificity, frequency, and function.
Detection of immunity *in vivo*.
Manipulation of the immune system.

Immunobiology ➔ Appendix I. Immunologists' Toolbox ➔ Isolation of lymphocytes.




Figure A.23. Peripheral blood mononuclear cells can be isolated from whole blood by Ficoll-Hypaque™ centrifugation. Diluted anticoagulated blood (left panel) is layered over Ficoll-Hypaque™ and centrifuged. Red blood cells and polymorphonuclear leukocytes or granulocytes are more dense and centrifuge through the Ficoll-Hypaque™, while mononuclear cells consisting of lymphocytes together with some monocytes band over it and can be recovered at the interface (right panel).

Search

This book All books
 PubMed

© 2001 by Garland Science

PROGRAM DESCRIPTION

**Centre d'Etude du
Polymorphisme Humain (CEPH):
Collaborative Genetic Mapping
of the Human Genome**

JEAN DAUSSET,* HOWARD CANN,*
DANIEL COHEN,* MARK LATHROP,*
JEAN-MARC LALOUEL,† AND RAY WHITEMAN¹

*Centre d'Etude du Polymorphisme Humain (CEPH), 27 rue Juliette Dodu, 75010 Paris, France; and †Howard Hughes Medical Institute and Department of Human Genetics, University of Utah Health Sciences Center, Salt Lake City, Utah 84132

Elsewhere in this issue of *Genomics* is the first consortium map, that of chromosome 10, from the CEPH collaboration to map the human genome genetically. The map is truly a collaborative achievement, in that the underlying genotypes represent the efforts of laboratories collaborating with each other and with CEPH to produce a primary genetic map of the genome, consisting of polymorphic markers placed at approximately 20-cM intervals along each of the human autosomes and the X chromosome. Such a map provides a tool for the systematic localization of genes that determine inherited diseases and of other genes of interest. Genetic localization can be the first step in the development of diagnostic tests and isolation of a disease-determining gene. The purpose of this program description is to provide information about CEPH and the basis and nature of the collaboration.

CEPH

The Centre d'Etude du Polymorphisme Humain (CEPH)² is a nonprofit research institute that makes available to the scientific community a valuable research resource. CEPH is committed to (1) make available to the scientific community DNA samples from a panel of reference families for the determination of genotypes for various DNA polymorphisms which may be used for the construction of the genetic map of the human genome and for other research areas dependent on access to such a common set of families, and (2) provide to the contributors of genotypes a compilation of all data that accumulate on the panel of families.

CEPH Collaboration

The CEPH collaboration to map the human genome was organized in 1984 to hasten construction of a primary human

genetic map with DNA polymorphisms (Botstein *et al.*, 1980). A key premise of the CEPH collaboration is that the human genetic map will be efficiently achieved by collaborative research on DNA from the same sample of families. To this end, CEPH provides to collaborating investigators high-quality cellular DNA produced from cultured lymphoblastoid cell lines (LCL) derived from each member of a reference panel of large nuclear families/pedigrees and a database contributed to and shared by these investigators. Collaborating investigators determine genotypes with their probes and the DNA from the CEPH panel to test the families for segregation of these genetic markers. They then contribute the genotypes to CEPH for preparation of a database which is returned to them for linkage analysis and map construction. As of October 1, 1989, 63 research laboratories in the United States (38), Canada (2), Europe (20), South Africa (2), Japan (2), and Australia (1) collaborate with CEPH in this manner.

CEPH Reference Family Panel

Families with large sibships, living parents, and grandparents are especially informative for linkage mapping (White *et al.*, 1985). From 100 families available from various sources, selected not for disease but for large sibship size, an initial group of 40 families was defined for the CEPH reference panel by the original group of collaborating investigators. Table 1 shows the geographic origins of these families and the contributors of the LCLs to CEPH. These are Caucasian families. The mean sibship size for these 40 families, based on those individuals for whom there are LCLs, is 8.3; no family has less than 6 offspring, and 23 families have 8 or more offspring. LCLs are available for all 4 grandparents in each of 29 families of the reference panel.

LCLs of the reference panel are stored in liquid nitrogen at three geographically separate repositories: Paris and Lyon, France; and Salt Lake City, Utah. These LCLs are not distributed by CEPH within or outside of the collaboration. They are used only as a source of DNA for the collaboration. LCLs for 11 of the panel families are available from the NIGMS Human Genetic Mutant Cell Repository located at the Coriell Institute for Medical Research in Camden, New Jersey.

Approximately 20 mg of DNA is prepared, as needed, from each LCL, and aliquots of 200 or 400 µg are distributed to each collaborating investigator. There is no charge to collaborating investigators for the DNA. The DNA is prepared by classical methods, scaled up to preparation of milligram amounts, which include lysis with proteinase K and SDS, extraction with phenol, and precipitation with isopropanol. The quality of each preparation of CEPH DNA is routinely controlled by testing for concentration, molecular size, digestibility with two different restriction enzymes, and contamination with vector sequences (Southern blot hybridized with a cosmid vector). In addition, each DNA preparation is hybridized with at least two highly variable ("minisatellite") probes (Wong *et al.*, 1987) to confirm identity of the LCL source and to detect contamination with DNA from another individual.

¹All authors are members of the CEPH Executive Committee.

²Founded in 1983 by J.D. and D.C.

SPECIAL FEATURE

TABLE 1
Sources of CEPH Family Panel

| | | |
|-----------------------------------|--------------------------|------------|
| Utah | 27 families ^a | R. White |
| Franco | 10 families | J. Dausset |
| Venezuela | 2 families ^b | J. Gusella |
| Pennsylvania (Old Order Amish) | 1 family ^c | J. Egeland |

^aLCLs from 9 families available from NIGMS Human Genetic Mutant Cell Repository, Camden, NJ.

^bLCLs from 1 of 2 families available from NIGMS Human Genetic Mutant Cell Repository.

^cLCLs available from NIGMS Human Genetic Mutant Cell Repository.

DNA Polymorphisms

The family panel DNA is being tested for at least 1200 DNA polymorphisms. The probes being used within the collaboration detect polymorphism within restriction enzyme sites of low copy number or unique DNA segments, due to varying numbers of tandemly repeated, relatively small sequences, or VNTRs (Nakamura *et al.*, 1987), and of centromere-associated alpha satellite DNA (Willard *et al.*, 1986). Some collaborating investigators have begun to use genetic markers with family panel DNA that are based on detection of length variations of very small sequences amplified by PCR (Weber and May, 1989; Litt and Luty, 1989). Phenotypes for classical, serological, and electrophoretic polymorphic markers are also available for the family panel.

CEPH Database

CEPH collaborating investigators have agreed on two basic rules concerning their participation within the collaboration: (1) A CEPH collaborating investigator is committed to screening the reference panel by determining genotypes for all 40 parent pairs with each probe and enzyme combination used and then following segregation in each informative family (at least one heterozygous parent) in his or her own laboratory or collaboratively. (2) Collaborating investigators are committed to sending genotypic data to CEPH for inclusion in the CEPH database no later than publication of the data themselves or of an article based on the data.

Genotypic data generated from family panel DNA are processed into uniform format by a set of programs developed at CEPH (J.-M.L.) for use with IBM PCs or compatible models and sent to all collaborating investigators. The data files thus prepared are sent to CEPH to be merged into the CEPH database.

There are two components of the database: The CEPH collaborative database is available only within the collaboration. Two classifications of data are recognized in the collaborative database, *unpublished* and *published*. The first are those data that have not been used for a publication. These are privileged data, requiring permission from the contributor for use (e.g., publication) by another collaborating investi-

gator. Published data are automatically available for inclusion in CEPH consortium maps (see below) and after a lag period will be released to the CEPH public database. After 2 years in the collaborative database, unpublished data become published data. The CEPH public database, currently being organized, will contain published data released from the collaborative database. Data in the public database will be available to the general scientific community.

Table 2 summarizes the contents of the CEPH collaborative database. As of July 1989, the database contains genotypic data for 1061 genetic markers localized to all the autosomes and the X chromosome (including the pseudoautosomal region). Approximately 20% of these marker systems have four or more alleles.

New CEPH Activities

As the primary map of the human genome nears completion, there is growing interest in a higher resolution genetic map, perhaps of the order of 1–2 cM. Availability of a higher resolution map will increase the efficiency and precision of localization of genes. In order to support construction of a high-resolution map of the genome, CEPH is in the process of increasing the family panel to 61 large nuclear families/pedigrees. LCLs from 21 additional families have already been received from Utah, and stocks of DNA are being prepared from them. The mean sibship size for the total of 61 families in the augmented panel is 8.5, and LCLs for all 4 grandparents are available for each of 44 families. These 21 families provide an additional advantage for genetic mapping in that they have already been genotyped for approximately 500 genetic markers used in the CEPH collaboration.

CEPH has undertaken a project to enhance the use of the primary map of the genome in localizing genes of interest. The idea is to collect and produce quantities of ready-to-label probes for the mapped primary markers and distribute these to biomedical scientists who wish to localize disease-determining genes and other genes of interest. Probes to be distributed will be those for markers chosen from CEPH consortium maps based on criteria that include heterozygote frequency and position on the genetic map of a chromosome. Collections of probes ("kits") will be available for each chromosome. By using the probes in a kit to test a large kindred or group of families in which a genetic disease with the appropriate chromosome assignment is segregating, an inves-

TABLE 2
CEPH Database

| Version | No. of contributing labs | No. of markers | No. of markers with 4 or more alleles | Date |
|---------|--------------------------|----------------|---------------------------------------|------------|
| V1 | 17 | 171 | 28 | April 1987 |
| V2 | 29 | 744 | 143 | March 1988 |
| V3 | 33 | 1061 | 204 | July 1989 |

tigator should be able to find linkage to one, two, and perhaps more markers if a sufficient number of informative meioses are available. Again, if data from a sufficient number of meioses are available, we would expect that a gene of interest without a chromosome assignment could be localized with markers from all of the kits. Investigators using these kits for primary mapped markers will be invited to contribute the genotypes they determine from families being tested with the probes to a database provided by CEPH. This project, being carried out in collaboration with the American Type Culture Collection, is sponsored by the National Institutes of Health.

Progress toward the Primary Genetic Map of the Human Genome

The number of markers for which there are genotypic data in the CEPH database suggests that the primary human genetic map is nearing completion. Partial or nearly complete³ primary linkage maps based on genotypes determined from reference panel DNA with probes from a single or small group of CEPH collaborating laboratories have been published for many of the chromosomes (see, for example, Donis-Keller *et al.*, 1987; O'Connell *et al.*, 1989; Lathrop *et al.*, 1988; Nakamura *et al.*, 1988; Warren *et al.*, 1989). CEPH consortium maps, the first of which appears in this issue of *Genomics*, will provide reference primary linkage maps of each chromosome based on the combined genotypic data within the collaboration.

CEPH Consortium Maps

The primary genetic map of the human genome, based on all genotypes determined from the CEPH families, will be communicated to the scientific community through a series of consortium maps, one for each chromosome. These maps will represent the ultimate validation of genotypic data in the CEPH database. Each consortium map will be prepared by a committee of collaborating investigators who have contributed genotypic data for markers localized to the particular chromosome. A chromosome-specific database, containing genotypes for all relevant markers, will be sent to members of the consortium map committee for the construction of genetic maps. These maps will be circulated within the committee for study and comparison. The committee will meet for the final analysis of these maps, which will be used in the preparation of the consortium map. The consortium map and a report will be published in *Genomics*. It is this process that led to the CEPH consortium map of chromosome 10 presented in this issue of *Genomics*.

As each consortium map is published, the underlying genotypic data will be released to the scientific community. The consortium maps will provide the basis for choosing the primary mapped markers for which kits of probes will be distributed by CEPH to the scientific community in order to

enhance the use of the genetic map for localization of genes that determine disease and other genes of interest.

REFERENCES

1. BOTSTEIN, D., WHITE, R. L., SKOLNICK, M., AND DAVIS, R. W. (1980). Construction of a genetic linkage map using restriction fragment length polymorphisms. *Amer. J. Hum. Genet.* 32: 314-331.
2. DONIS-KELLER, H., GREEN, P., HELMS, C., CARTINHOUR, S., WEIFFENBACH, B., STEPHENS, K., KEITH, T., BOWDEN, D., SMITH, D., LANDER, E., BOTSTEIN, D., AKOTS, G., REDIKER, K., GRAVIUS, T., BROWN, V., RISING, M., PARKER, C., POWERS, J., WATT, D., KAUFFMANN, E., BRICKER, A., PHIPPS, P., MULLER-KAHLE, H., FULTON, T., NG, S., SCHUMM, J., BRAMAN, J., KNOWLTON, R., BARKER, D., CROOKS, S., LINCOLN, S., DALY, M., AND ABRAHAMSON, J. (1987). A genetic linkage map of the human genome. *Cell* 51: 319-337.
3. LATHROP, M., NAKAMURA, Y., O'CONNELL, P., LEPPERT, M., WOODWARD, S., LALOUEL, J.-M., AND WHITE, R. (1988). A mapped set of genetic markers for human chromosome 9. *Genomics* 3: 361-366.
4. LITT, M., AND LUTY, J. A. (1989). A hypervariable microsatellite revealed by *in vitro* amplification of a dinucleotide repeat within the cardiac muscle actin gene. *Amer. J. Hum. Genet.* 44: 397-401.
5. NAKAMURA, Y., LEPPERT, M., O'CONNELL, P., WOLFF, R., HOLM, T., CULVER, M., MARTIN, C., FUJIMOTO, E., HOFF, M., KUMLIN, E., AND WHITE, R. (1987). Variable number of tandem repeat (VNTR) markers for human gene mapping. *Science* 235: 1616-1622.
6. NAKAMURA, Y., LATHROP, M., O'CONNELL, P., LEPPERT, M., BARKER, D., WRIGHT, E., SKOLNICK, M., KONDOLEONI, S., LITT, M., LALOUEL, J.-M., AND WHITE, R. (1988). A mapped set of DNA markers for human chromosome 17. *Genomics* 2: 302-309.
7. O'CONNELL, P., LATHROP, G. M., NAKAMURA, Y., LEPPERT, M. L., ARDINGER, R. H., MURRAY, J. L., LALOUEL, J.-M., AND WHITE, R. (1989). Twenty-eight loci form a continuous linkage map of markers for human chromosome 1. *Genomics* 4: 12-20.
8. WARREN, A. C., SLAUGENHAUPT, S. A., LEWIS, J. G., CHAKRAVARTI, A., AND ANTONAKAKIS, S. E. (1989). A genetic linkage map of 17 markers on human chromosome 21. *Genomics* 4: 579-591.
9. WEBER, J. L., AND MAY, P. E. (1989). Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction. *Amer. J. Hum. Genet.* 44: 388-396.
10. WHITE, R., LEPPERT, M., BISHOP, T., BARKER, D., BERKOWITZ, J., BROWN, C., CALLAHAN, P., HOLM, T., AND JEROMINSKI, L. (1985). Construction of linkage maps with DNA markers for human chromosomes. *Nature (London)* 313: 101-105.
11. WILLARD, H. F., WAYE, J. S., SKOLNICK, M. H., SCHWARTZ, C. E., POWERS, V. E., AND ENGLAND, S. B. (1986). Detection of restriction fragment length polymorphisms at the centromeres of human chromosomes by using chromosome-specific satellite DNA probes: Implications for development of centromere-based genetic linkage maps. *Proc. Natl. Acad. Sci. USA* 83: 5611-5615.
12. WONG, Z., WILSON, V., PATEL, I., POVEY, S., AND JEFFREYS, A. J. (1987). Characterization of a panel of highly variable minisatellites cloned from human DNA. *Ann. Hum. Genet.* 51: 269-288.

³ A primary linkage map of a chromosome cannot be considered complete until it contains markers for, or quite close to, the telomeres.